Ravulizumab
Products Ravulizumab was approved in the United States in 2018, in the EU in 2019, and in many countries in 2020 as a concentrate for the preparation of an infusion solution (Ultomiris). Structure and properties Ravulizumab is an IgG2/4K monoclonal antibody produced by biotechnological methods. Effects Ravulizumab (ATC L04AA43) binds to complement protein C5, inhibiting … Ravulizumab
